news @ Unravel Bio
2024
Unravel Biosciences and PECET Announce Collaboration to Conduct Clinical Trials of RVL-001 in Rett Syndrome and Pitt Hopkins Syndrome in Colombia
Ocotber 24 2024. Study site selection and finalization of clinical trial agreement final step toward initiation of RVL-001 proof-of-concept clinical studies early next year.
Collaborative Research Aims to Discover Effective Treatments for Marine Mammals Poisoned by Toxic Algae
October 29, 2024. Zymo Research, Unravel Biosciences, and Channel Islands Marine & Wildlife Institute team up to combat increasing cases of domoic acid poisoning in sea lions.
Unravel Biosciences and The Jackson Laboratory Announce Collaboration to Accelerate the Discovery of Promising Drugs for Diseases with High Unmet Need
September 17, 2024. The collaboration will allow for a more rapid and efficient approach to the identification and pre-clinical evaluation of potential drug candidates across multiple diseases to advance into clinical testing.
Unravel Biosciences and Pitt Hopkins Research Foundation Announce Collaboration to Conduct Clinical Study of RVL-001 in Pitt Hopkins Patients
June 11, 2024. Pitt Hopkins Research Foundation to fund proof of concept clinical trial in Colombia to assess the efficacy of vorinostat (RVL-001) in patients with Pitt Hopkins Syndrome.
Unravel Biosciences and CSNK2A1 Foundation Announce Expansion of Collaboration to Identify Drug Candidates for Okur-Chung Neurodevelopmental Syndrome
August 28, 2024. New study will use Unravel's AI platform to stratify patients into subgroups based on their likelihood to respond to prioritized drugs identified in earlier phase of research.
Unravel Biosciences Receives FDA Orphan Drug Designation for Vorinostat (RVL-001) as a Treatment for Rett Syndrome
May 28, 2024. Received Orphan Drug Designation from the United States Food and Drug Administration (FDA) for vorinostat (RVL-001) as a treatment for Rett Syndrome. Initiation of global clinical development program underway.
Unravel Announces Collaboration with Vanderbilt University Medical Center to Support U.S. Clinical Study in Rett Syndrome
May 14, 2024. Multisite trial run by Vanderbilt will evaluate repurposed FDA-approved drugs as treatment options for Rett syndrome patients, including vorinostat (RVL-001) predicted by Unravel's BioNAV platform.
Unravel Announces Initiation of RVL001 Clinical Trial Material Manufacturing
March 19, 2024. Announced a manufacturing and development partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture RVL001 clinical trial material for use in upcoming Rett syndrome clinical trials in the US and Colombia.
Unravel Initiates RVL-001 Clinical Program in Colombia for Rett Syndrome With Clinical Trial Tool Translation
February 13, 2024. IRB approval received to develop validated translations of Rett Syndrome Behavioral Questionnaire into Spanish, a key step for clinical trial initiation.
Vanderbilt University receives $13M grant to fund multisite Rett syndrome clinical trial
January 9, 2024. Unravel Biosciences’ in silico, preclinical datasets, and pre-IND feedback from the FDA led to the inclusion of vorinostat in a grant-funded multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.
CHOPS Foundation Initiates AI-Driven Therapeutics Discovery Program With Unravel Biosciences
January 5, 2024. The CHOPS Foundation’s strategic approach will tackle an ultra-rare disorder by joining forces with Cornelia de Lange syndrome families and leverage Unravel’s BioNAV™ platform to rapidly identify therapeutic mechanisms that can be tested clinically.
2023
CURE AP-4 ENGAGES UNRAVEL BIOSCIENCE IN PIONEERING AI-DRIVEN DRUG DISCOVERY FOR ULTRA-RARE CNS DISEASE
December 5, 2023. Partnership will generate clinical data from patients globally to accelerate identifying and developing therapeutics for AP-4 hereditary spastic paraplegias and expanding to other related disorders through innvoative patient stratification.
Vascular Perfusion Solutions and Unravel Biosciences announce partnership to modulate endothelial activation during heart preservation to improve heart transplant outcomes
November 27, 2023. Co-development of a cardiac perfusion solution aims at extending viability of hearts in transport and reduce acute organ rejection.
MeCo Diagnostics and Unravel Biosciences announce a prostate cancer biomarker and drug discovery partnership
October 26, 2023. Partnership unlocks synergies to rapidly identify and evaluate novel biomarker-targeted therapies for solid tumors, starting with prostate cancer.
George Church, Julie Clauss join Unravel Biosciences advisory board
September 14, 2023. Renowned advisors’ deep expertise in pharma partnering, drug commercialization, and technology innovation supports the next stage of company growth.
CSNK2A1 Foundation awards grant to Unravel Biosciences to accelerate orphan CNS drug development
August 18, 2023. Award from CSNK2A1 Foundation advances effort to identify new treatments for Okur-Chung Neurodevelopmental Syndrome (OCNDS) and expands Unravel’s OCNDS and sleep disorder portfolio.
Unravel Biosciences received grant to support neurodegenerative target discovery
March 29, 2023. Award from MGH CCXDP advances effort to identify new treatments for X-linked dystonia Parkinsonism (XDP)
Unravel announces positive feedback to FDA pre-IND meeting
February 15, 2023. FDA pre-IND feedback provides a clear path forward to initiate proof-of-concept clinical study of RVL001 in Rett Syndrome patients later this year
Unravel announces rareSHIFT™, an end-to-end solution for drug discovery
September 19, 2023. rareSHIFT™ provides industry and foundations access to Unravel's drug discovery engine to accelerate patient-centered drug development while expanding the Unravel drug pipeline.
2022
Unravel licenses Wyss Institute at Harvard's technology platform to accelerate CNS drug discovery
September 27, 2022. Unravel has exclusively licensed a patent for treating Rett syndrome and CKDL5 deficiency disorder along with cutting edge CogniXense cognitive screening technology, built on years of DARPA funding. This license will enable Unravel to progress to clinical stage and expand its asset portfolio for indications beyond Rett syndrome.
Unravel partners with TMA Precision Health to advance Rett syndrome therapy to the clinic
July 5, 2022. Unravel has partnered with TMA Precision Health to accelerate clinical translation of its proprietary orla liquid therapeutic for Rett syndrome.
RTK Group announces investment in Unravel Biosciences
June 14, 2022. Expands RTK Group's biopharma investment portfolio into startups developing platform technologies having high potential for disruptive innovation and brings Unravel's innovative patient stratification approach to the forefront of therapeutics discovery.